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Abstract Summary: 
Increasing prevalence of asthma and COPD has increased use of long acting inhalers. Different
inhalers with patented delivery systems have kept costs high and inhalers among the highest
expenditure items in ambulatory care in Scotland. There was a 136.8% increase in their utilisation
between 2001 - 2017 alongside a 195.7% increase in expenditure. This is being addressed with
branded 
Introduction: 
There is increasing prevalence of asthma and chronic obstructive pulmonary disease particularly
among Western countries. Longer acting formulations of beta agonists and steroids (LABA/ ICS)
have improved care with short acting beta agonists (SABAs) now principally used for rescue. The
concerns with inhaler technique and compliance have resulted in different inhalers with new patented
delivery systems. This has kept costs high as it is challenging to change inhalers if patients are stable
on a particular inhaler, different to switching between generic and patented PPIs and statins.
However as most standard medicines are now available as low cost generics, inhaler costs have
become highly visible and are now among the highest expenditure items in ambulatory care in
Scotland. This has resulted in initiatives in recent years to consider lower costs branded generic
LABAs/ ICS. 
Methods: 
Assessing utilization (items dispensed) and expenditure of different inhalers used for asthma and
COPD between 2001 and 2017 in Scotland via national databases alongside Health Board initiatives.
Results: 
144 different inhalers were included in the analysis. There was a 136.8% increase in their utilisation
between 2001 and 2017 alongside a 195.7% increase in total expenditure. Increasing use of LABA/
ICS, and more recently long acting anti-muscarinics, have driven increasing utilisation with limited
use of SABAs. This is very different to the PPIs, statins, and SSRIs where expenditures have
appreciably fallen in recent years despite significantly increased volumes following generics. This is
changing with greater use of branded generic LABAs/ ICS in Scotland in recent years. 
Conclusions: 
Concerns with techniques and switching have resulted in inhalers not following other high-volume
drug classes once generics become available, although starting to change. Concerns with the advice
given to patients about the inhalers still needs addressing. Further research is ongoing to help
Scottish Health Boards cope with inhaler expenditure whilst maintaining good care. 
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